Panacea Acquisition Corp (NUVB) News

Form 8-K - Current report

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable...

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

Presentation will highlight the comparable efficacy and safety of taletrectinib across pivotal studies and different ethnicities and world...

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Nuvation Bio to Present at The Citizens Life Sciences Conference

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements